Not Yet RecruitingNot Applicable

Role of SPECT/CT of Bone Scan in Charactarization of Bone Lesions

120 participantsStarted 2025-11

Plain-language summary

This observational study aims to assess the diagnostic value of SPECT/CT of 99mTc-MDP bone scintigraphy in differentiating begnin from malignant bone lesions. The main question it aims to answer is: ●Can SPECT/CT-derived quantitative parameters (SUVmax, SUVmean) accurately differentiate between begnin and malignant bone lesions in clinical settings? Final diagnostic impression: confirmed by biopsy (if available), or through multidisciplinary radiologic-clinical correlation

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any age referred for 99mTc-MDP SPECT/CT * Clinical suspicion of either metastatic or degenerative etiology Exclusion Criteria: * Case with double malignancies * Pregnant patients * Severely ill patients

What they're measuring

To measure SUVmax and SUVmean of bone lesions using quantitative SPECT/CT.

Timeframe: Baseline

To compare these values between malignant and degenerative lesions confirmed by clinical, histological, or radiological follow-up.

Timeframe: Baseline

Trial details

NCT IDNCT07248033

SponsorMennaTalla Saber Sabet Mohamed

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11

Contact for this trial

MennaTalla Saber Sabet

01151322001 Sebastian.kuroshitsuji1@gmail.com

View on ClinicalTrials.gov More Bone Lesions trials